GlassScriptPhysician profile
James P Lagrew
NPI 1154767457
$5,041.55
in general payments reported to CMS, 2019-2025
32 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2020: $180 · 2021: $543 · 2022: $786 · 2023: $792 · 2024: $744 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078 · Education: $85.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.76 |
| Education | $85.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,129.17 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $506.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $458.88 | 2019-2024 | |
| Lilly USA, LLC | $407.78 | 2019-2024 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $294.65 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $287.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $264.61 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.32 | 2023-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $153.40 | 2019-2025 | Nemluvio, Epsolay, Twyneo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.20 | 2019-2023 | Jublia |
| Pfizer INC. | $128.14 | 2019-2023 | |
| Amgen INC. | $126.51 | 2019-2024 | Otezla |
| Merz North America, INC. | $117.61 | 2019-2021 | |
| Genentech USA, INC. | $112.49 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $109.67 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $95.20 | 2019-2025 | Klisyri |
| Leo Pharma INC. | $73.85 | 2021-2022 | |
| Ucb, INC. | $69.02 | 2019-2024 | Bimzelx |
| Lnhc, INC | $60.39 | 2025 | Zelsuvmi |
| Allergan, INC. | $56.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $47.21 | 2021-2025 | |
| Organogenesis INC. | $31.19 | 2024 | |
| Epi Health, LLC | $29.60 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $28.34 | 2025 | |
| Dermira, INC. | $25.03 | 2019 | |
| Incyte Corporation | $21.96 | 2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $15.67 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Cipher Pharmaceuticals US LLC | $13.84 | 2025 | Spinosad, Natroba |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Encore Dermatology INC. | $11.93 | 2019 | |
| Prugen, INC. Pharmaceuticals | $9.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lagrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.